Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: A critical role of interferon-γ

Journal of Immunotherapy

Volumn 34, Issue 1, 2011, Pages 65-75

  Viaud, Sophie ^a,b,c   Ploix, Stéphanie ^a,b   Lapierre, Valérie ^b,d   Théry, Clotilde ^a,e,f   Commere, Pierre Henri ^a,b   Tramalloni, Dominique ^b,d   Gorrichon, Kevin ^b,d   Virault Rocroy, Pauline ^b,d   Tursz, Thomas ^a,b,c   Lantz, Olivier ^a,e,f   Zitvogel, Laurence ^a,b,c   Chaput, Nathalie ^a,b,d  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d Cell Processing Unit   (Switzerland)

^e INSTITUT CURIE   (France)

^f PSL RESEARCH UNIVERSITY   (France)

Author keywords

cancer; clinical trials; dendritic cells; exosomes; IFN g

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CYTOKINE RELEASE; DENDRITIC CELL; EXOSOME; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EXOSOMES; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC;

EID: 78650672083     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181fe535b     Document Type: Article

References (39)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384.
3. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253-1261.
4. Banchereau J, Briere F, Caux C. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
5. Banchereau J, Schuler-Thurner B, Palucka AK, et al. Dendritic cells as vectors for therapy. Cell. 2001;106:271-274.
6. Fong L, Engleman EG. Dendritic cells in cancer immuno-therapy. Annu Rev Immunol. 2000;18:245-273.
7. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003;15:138-147.
8. Yang L, Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci USA. 2005;102:4518-4523.
9. Erdmann M, Schuler-Thurner B. Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines. Methods Mol Biol. 2010;595:149-163.
10. Zitvogel L, Regnault A, Lozier A. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998;4:594-600.
11. Andre F, Chaput N, Schartz NE. Exosomes as potent cell-free peptide-based vaccine: I. dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. 2004;172:2126-2136.
12. Chaput N, Schartz NE, Andre F. Exosomes as potent cell-free peptide-based vaccine: II. exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol. 2004;172:2137-2146.
13. Thery C, Duban L, Segura E, et al. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol. 2002;3:1156-1162.
14. Hsu DH, Paz P, Villaflor G. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J Immunother. 2003;26:440-450.
15. Lamparski HG, Metha-Damani A, Yao JY. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods. 2002;270:211-226.
16. Thery C, Regnault A, Garin J. Molecular characterization of dendritic cell-derived exosomes: selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999;147: 599-610.
17. Escudier B, Dorval T, Chaput N. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC)-derived exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005;3:10.
18. Morse MA, Garst J, Osada T. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3:9.
19. Chaput N, Flament C, Viaud S. Dendritic cell-derived exosomes: biology and clinical implementations. J Leukoc Biol. 2006;80:471-478.
20. Viaud S, Terme M, Flament C. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One. 2009;4:e4942.
21. Ruffner MA, Kim SH, Bianco NR, et al. B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function. Eur J Immunol. 2009;39:3084-3090.
22. Segura E, Amigorena S, Thery C. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis. 2005;35: 89-93.
23. Segura E, Nicco C, Lombard B. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood. 2005;106:216-223.
24. Sprent J. Direct stimulation of naive T cells by antigen-presenting cell vesicles. Blood Cells Mol Dis. 2005;35:17-20.
25. Viaud S, Thery C, Ploix S. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res. 2010;70: 1281-1285.
26. Hwang I, Shen X, Sprent J. Direct stimulation of naive T cells by membrane vesicles from antigen-presenting cells: distinct roles for CD54 and B7 molecules. Proc Natl Acad Sci USA. 2003;100:6670-6675.
27. Dufour E, Carcelain G, Gaudin C, et al. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. J Immunol. 1997;158:3787-3795.
28. Wolfers J, Lozier A, Raposo G. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7:297-303.
29. Firat H, Tourdot S, Ureta-Vidal A, et al. Design of a poly-epitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur J Immunol. 2001;31:3064-3074.
30. Dai S, Wei D, Wu Z. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colo-rectal cancer. Mol Ther. 2008;16:782-790.
31. Higano CS, Schellhammer PF, Small EJ. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
32. Small EJ, Schellhammer PF, Higano CS. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24: 3089-3094.
33. Ostrowski M, Carmo NB, Krumeich S. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12:19-30.
34. Raposo G, Nijman HW, Stoorvogel W. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183:1161-1172.
35. Segura E, Guerin C, Hogg N, et al. CD8+ dendritic cells use LFA-1 to capture MHC-peptide complexes from exosomes in vivo. J Immunol. 2007;179:1489-1496.
36. Qazi KR, Gehrmann U, Domange Jordo E, et al. Antigen-loaded exosomes alone induce Th1-type memory through a B cell-dependent mechanism. Blood. 2009;113:2673-2683.
37. Hao S, Bai O, Li F, et al. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology. 2007;120:90-102.
38. Ghiringhelli F, Menard C, Puig PE. Metronomic cyclophos-phamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56: 641-648.
39. Taieb J, Chaput N, Schartz N. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol. 2006;176:2722-2729.